Biotech industry is enjoying a strong IPO resurgence

11/21/2013 | Financier Worldwide magazine

The biotech initial public offering market is experiencing a strong revival this year after several dry years, Richard Summerfield writes. In the first half of 2013 alone, the value of biotech IPOs surpassed $1.7 billion, more than 2011 and 2012 together. Several factors boosted the popularity of biotech IPOs, including the number of drugs approved last year and the adoption of the Jumpstart Our Business Startups Act.

View Full Article in:

Financier Worldwide magazine

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park